

# Index

**Note:** Page numbers followed by an *f* refer to figures. Page numbers followed by a *t* refer to tables. Page numbers in **bold** indicate an in-depth discussion.

## A

A1C (glycosylated hemoglobin), 2, 7–8, 19, **30–33**, 69, 101  
abnormal cry, 117*t*  
abortion. *See* spontaneous abortion (SAB)  
acidemia, 75, 113  
adolescent, 9, 141  
albumin, 33, 115  
albumin-to-creatinine ratio, 11*t*, 12  
alcohol, 2, 59–60  
Alpha-fetoprotein ( $\alpha$ FP), 83, 84*t*  
American Academy of Pediatrics, 118, 129  
American College of Obstetricians and Gynecologists (ACOG), 27–28, 44, 69–70, 96–97, 118, 129, 147  
American Diabetes Association, 10–12, 15–19, 26–27, 44–48, 51–58, 70, 128–133  
American Heart Association, 118  
amino acids, 45, 56  
amniocentesis, 82, 84*t*–85*t*, 85–87, 92  
amniotic fluid, 56, 83, 85–89  
amniotic fluid index (AFI), 89  
anemia, 58–59, 133  
anencephaly, 83, 84*t*, 110*t*  
aneuploidies, 82, 84*t*, 85  
angiotensin receptor blockers (ARBs), 12  
angiotensin-converting enzyme (ACE) inhibitors, 12

antenatal insulin, **70–74**, 72*t*, 73*f*  
antenatal testing, 88–91, 89*f*–90*f*  
antiemetic medication, 100  
antihistamine, 99  
ASA (acetylsalicylic acid), 11*t*  
aspart, 16, 18*t*, 71, 72*t*  
aspart glulisine, 18*t*, 71, 72*t*  
asphyxia, 6*t*, 89, 108, 111–113, 112*t*, 116*t*  
aspirin. *See* ASA (acetylsalicylic acid)  
autoimmune gastritis, 58

## B

barrier methods, 139, 140*t*  
basal insulin, 16, 69, 71  
betamethasone, 75  
biguanide, 76  
bilirubin load, 115  
biochemical disturbances, 7  
biochemical immaturity, 115  
biophysical profile, 82, 85*t*, 89, 103  
biotin, 47*t*, 131*t*  
birth control methods. *See* contraception  
birth injury, 6*t*, 108, 112–113, 112*t*, 116*t*, 118*t*  
birth trauma, 44, 93  
blood glucose. *See also* glucose; hyperglycemia; hypoglycemia; self-monitoring of blood glucose (SMBG)  
    calorie restriction, 44–45  
    congenital anomalies, 8  
    factors affecting, 31  
    fasting, 71  
    labor and delivery, 75, 75*t*–76*t*  
    normoglycemia, 27

- postprandial, 15*t*, 16, 27, 29–30, 52
- prepregnancy, 14–17
- blood loss, 32*t*
- blood pressure, 12, 61, 102, 109, 119, 128, 138–141. *See also* hypertension; preeclampsia
- BMI (body mass index), 14, 41–44, 43*t*, 51, 119, 132, 142*t*
- brain injury, 117
- breast-feeding, 49*t*, 70, 70*f*, 126–127, **129–133**, 130*t*, 143*t*
- bronchopulmonary dysplasia, 114
- C**
- caffeine, 59, 59*t*, 99, 99*t*, 133
- calcium, **47*t***, **58**, 114, 131*t*
- calcium channel blockers, 75, 101
- calcium homeostasis, 58
- calories, 50*t*
  - amount, 54*t*–55*t*
  - balance, 15*t*
  - carbohydrates, 50, 52–53, 58, 60, 100
  - dietary fat, 56–57
  - hyperglycemia, 44–45
  - obesity, 44–45
  - postpartum, 130
  - protein, 56
  - restriction, 44–45
  - sufficient, 44, 48
  - supplemental, 129
- capillary glucose monitoring, 26–28, 31. *See also* self-monitoring of blood glucose (SMBG)
- carbohydrate, 50, **52–53**, 58, 60, 100
  - continuous subcutaneous insulin infusion (CSII), 15–17
  - dietary fiber, 50, 53, 54*t*–55*t*
  - dietary reference intakes (DRIs), 46*t*, 131*t*
  - glucose levels, 31
  - glycemic index (GI), 55
  - homeostasis, 116
  - insulin dosing, 71–72, 74
  - insulin pump, 73
  - macronutrients, 133
  - management, 14
  - meal planning, 48–50
  - nonpharmacologic treatment, 98, 99*t*
  - prepregnancy, 14
  - protein, 130
- cardiac
  - arrest, 117*t*
  - disease, 5*t*, 12–13, 113*t*
  - hypertrophy, 6*t*, 112
- cardiomyopathy, **111–112**, 128
- cardiovascular disease (CVD), 14, 57, 132, 138, 141, 146
- cardiovascular malformation, 111
- catheter, 17, 86, 117, 118*t*
- caudal regression syndrome, 110
- cell-free fetal DNA screening, 82, 85–86
- central nervous system (CNS), 57, 103, 110*t*, 113
- cephalohematoma, 112*t*
- cerebral palsy, 75
- cesarean section, 5*t*, 13, 44, 75–76, 91–93, 128, 147
- cholesterol, 15, 27, 56, 141
- Choose Your Foods: Exchange Lists for Meal Planning*, 48
- Choose Your Foods: Plan Your Meals*, 48
- chorionic villus sampling (CVS), 82, 84*t*, 86
- chromium, 47*t*, 58–59, 132*t*
- chromosomal abnormalities, 83
- chromosomal aneuploidy, 83, 85–86, 88
- colostrum, 127
- combination injectable contraceptives (CIC), 141
- combination oral contraceptives (COC), 138, 140*t*, 141
- congenital
  - anomalies, 2, 6–8, 71, 88, **102–103**, 110–111, 116*t*–118*t*, 139
  - heart disease, 110*t*, 112
  - malformations, 6, 32, 83, 88, 108
- continuous glucose monitoring (CGM), **30–31**, 74
- continuous interstitial glucose monitoring, 26, **30–31**
- continuous subcutaneous insulin infusion (CSII), 15–17
  - insulin pumps, 15, 68, **73–75**, 102

- contraception  
 barrier methods, 139, 140*t*  
 condoms, 139, 140*t*  
 with diabetes, 138–139, 140*t*,  
 141, 142*t*–143*t*, 144–147,  
 144*t*, 148*t*  
 diaphragm, 139, 140*t*  
 efficacy, 2  
 estrogen/progestin methods, 140*t*  
 failure rates, 2  
 fertility awareness, 140*t*  
 gestational diabetes mellitus  
 (GDM), 138–139  
 hormonal, 140*t*, 141, 142*t*–143*t*  
 hypertension, 139, 141, 142*t*,  
 145–146  
 implants, 138, 140*t*, 142*t*, **145**,  
 146–147  
 injectable, 138–139, 140*t*, 142*t*,  
 145–146  
 intrauterine devices (IUDs), 138,  
 140*t*, **141**, 142*t*, **144–145**,  
 144*t*  
 long-acting reversible  
 contraceptive (LARC), 9,  
 138, 140*t*, **141**, 142*t*–144*t*,  
**144–145**  
 methods, 2, 9  
 non-LARC hormonal, 140*t*,  
 144–147  
 obesity, 142*t*  
 oral, 138–139, 140*t*, 141  
 postpartum, 138, 143*t*, 147, 148*t*  
 pregnancy counseling, 9  
 pregnancy rate, 140*t*  
 progestin-only oral  
 contraception (PO-OC), 138,  
 140*t*, **146–147**  
 rhythm method, 140  
 spermicide, 139, 140*t*  
 sterilization, 9, 13, 138–139,  
 140*t*, **147**, 148*t*  
 subcutaneous implant, 138  
 transvaginal hormonal, 139  
 unintended pregnancy rates, 140*t*  
 vaginal sponge, 140*t*  
 contra-insulin hormone, 31  
 copper IUD (Cu-IUD), 142*t*, 144–145
- cord-blood serum C-peptide levels, 28  
 corticosteroids, 75, 96, 101–102  
 cortisol, 31, 70, 73  
 counseling, 2–3, **9–11**, 9*t*  
 creatinine level, 11*t*, 12–13, 13*t*, 102  
 cystic fibrosis, 84*t*
- D**  
 dawn phenomenon, 17  
 degludec, 18*t*, 71  
 dehydration, 33*t*, 97  
 delivery, 5*t*, 82, 91–93, 92*t*, 103. *See*  
*also* preterm  
 depression, 128–129  
 desogestrel, 146  
 detemir (Levemir), 16, 18*t*, 71, 100  
 dexamethasone, 75  
 dextrose, 60, 75*t*–76*t*, 93, 117  
 diabetes. *See also* gestational diabetes  
 mellitus (GDM); type 1 diabetes  
 (T1D); type 2 diabetes (T2D)  
 complications, 10, 96, 97–103,  
 99*t*  
 congenital anomalies,  
**102–103**  
 diabetic ketoacidosis (DKA),  
 5*t*, 17, 33–34, 33*t*, 75, 100,  
**102**  
 hyperemesis and  
 gastroparesis, **97–100**, 99*t*  
 preeclampsia, **101–102**  
 preterm birth, 100–101  
 future pregnancies, 3  
 patient history, 11  
 preexisting, 2, **5–8**, 5*t*–9*t*, 15, 19,  
 26, 30, 32, 45–48, 46*t*–47*t*, 61,  
 68–72, 82, 88, 91–93, 100–  
 103, 110–119, 126–128, 133  
 pregnancy lifestyle management,  
 41, **43–61**, 43*t*, 46*t*–47*t*,  
 49*t*–51*t*, 54*t*–55*t*, 59*t*  
 testing, 3  
 diabetic ketoacidosis (DKA), 5*t*, 17,  
 33–34, 33*t*, 75, 100, **102**  
 diabetic sequelae, 138  
 diabetogenic stress, 69  
 diagnostic testing, 83, 84*t*, 85–86  
 diaphragm, 139, 140*t*

dietary control, 14, 70  
 dietary fat, 50, **56–57**  
 dietary fiber, 50, **53**, 54*t*–55*t*  
*Dietary Guidelines for Americans, 2010*  
 (U.S. Department of Agriculture,  
 Center for  
 Nutrition Policy and  
 Promotions 2012), 57  
 dietary reference intakes (DRIs), 14,  
 46, 46*t*–47*t*, 131*t*–132*t*  
*Dietary Reference Intakes for Vitamin D*  
*and Calcium (IOM 2010)*, 58  
*Dietary Reference Intakes: The Essential*  
*Guide to Nutrient Requirements*  
 (Institute of Medicine IOM 2006),  
 41, 46*t*–47*t*  
 dietician, 41, 46  
 dimenhydrinate, 99  
 diphenhydramine, 99  
 DNA testing, 82, 84*t*, 85  
 docosahexaenoic acid (DHA), 57  
 Doppler ultrasound, 90  
 Doppler velocimetry, 85*t*  
 Down's syndrome, 83  
 doxylamine, 99  
 dyslipidemia, 12, 56, 119

**E**  
 education, 9*t*, 14, 17, 34, 49, 53  
 eicosapentaenoic acid, 57  
 electrocardiogram, 11*t*, 13  
 electrolytes, 34, 97, 99*t*, 102, 127  
 elemental iron supplementation, 58  
 energy, 27, 45–46, **50–52**, 56, 69,  
 75*t*, 133  
     lactation, 130, 130*t*  
 erythremia, 6*t*, 115–166, 118*t*  
 erythropoietin therapy, 32*t*  
 estimated average requirement (EAR),  
 133  
 estimated date of delivery (EDD), 87  
 estimated due date, 3  
 estimated energy requirement (EER),  
 51, 51*t*  
 estriol, 85  
 estrogen, 70, 138  
 euglycemia, 108  
 exercise, 28, 51*t*, 52, 70–71, 74, 132

glucose levels with, 29, 31  
 prepregnancy assessment, 11, 14,  
 16–17  
     as treatment modality, 61  
 exogenous surfactant, 114  
 eye exams, 9, 12. *See also* retinal;  
 retinopathy

**F**  
 family planning, 3, 9  
 fasting glucose level, 19, 61  
 fasting plasma glucose, 19, 27, 48, 71,  
 88  
 fat  
     dietary, 50, **56–57**  
     saturated fat (SFA), 15, 56  
     trans, 15  
 fatty acids, 33, 56, 57  
 fetal  
     acidemia, 75  
     activity, 84*t*  
     anatomy, 82, 88  
     central nervous system, 57  
     circulation, 45  
     death, 102, 111  
     defect, 82–83, 84*t*  
     erythropoiesis, 58  
     growth, 45, 52–53, 69, 82, 103  
     hyperinsulinemia, 87, 103, 111  
     hypoxia, 93, 103  
     lung maturity, 85*t*, 87, 101  
     macrosomia (*See* macrosomia)  
     malformation, 57, 88  
     monitoring, 93, 113  
     organogenesis, 7, 10, 69, 88  
     overgrowth, 44  
     pancreas, 114  
     surveillance, 5, 82–83, 84*t*, 88,  
     91–92  
     ultrasound, 88, 109  
 fetal growth restriction (FGR), 85*t*, 90  
 fetal heart rate (FHR), 82, 89, 89*f*–90*f*,  
 102  
 fetal movement (FM), 88, 89*f*  
 fetal-placental growth, 50  
 fetoplacental unit, 69  
 $\alpha$ -fetoprotein, 82  
 fetus. *See* fetal

fiber. *See* dietary fiber  
 fluorescence in situ hybridization (FISH), 86  
 folate, 2, 47*t*, 57–58, 131*t*  
 folic acid, 11*t*, 15, 57–59, 99, 99*t*  
 food safety, 2, 59–60, 59*t*  
 fructosamine, 33

## G

gastric emptying, 29  
 gastroenteropathy, 10  
 gastroparesis, 97–100, 99*t*  
 genetics, 2, 10, 82–83, 84*t*–85*t*, 85–87  
 gestational age, 27, 82, 108, 116*t*  
 gestational diabetes mellitus (GDM).  
*See also* insulin  
   breast-feeding, 129–130  
   calorie restriction in obese patients, 44–45  
   contraception, 138–139  
   counseling, 3  
   fetal overgrowth, 56  
   insulin therapy, 16  
   meal plans, 49  
   medical nutrition therapy (MNT), 48  
   medication management, 68  
   metabolic changes in pregnancy, 68–70, 70*f*  
   obesity, 44–45  
   postpartum, 126–128  
   preterm birth, 100–101  
   previous, 18–19  
   self-monitoring of blood glucose (SMBG), 29–30  
   vaginal delivery, 82  
 gestational hypertension, 76  
 gestational weight gain, 45  
 ginger capsules, 98  
 glargine (Lantus), 16, 18*t*, 71, 100  
 glucagon, 17, 74, 117  
 glucose, 45  
   concentration, 26–31, 33, 71, 73–75, 75*t*–76*t*, 112, 114, 116  
   continuous glucose monitoring (CGM), 26, 30–31, 74  
   homeostasis, 109, 114, 116–117, 117*t*

intolerance, 31  
 levels  
   control, 2–3, 111  
   with exercise, 29, 31  
   factors affecting, 31  
   fasting, 19, 27, 48, 61, 88  
   intermittent capillary, 26–28, 31  
   postprandial, 15*t*, 16, 27, 29–30, 52  
   preprandial, 26, 30  
   prepregnancy, 14–17  
   self-monitoring of blood glucose (SMBG), 26–30, 32, 46, 49, 53, 128, 130  
   spontaneous abortion (SAB), 8  
 maternal, 27, 29, 31, 52, 75, 93, 110, 114  
   monitoring, 26–31  
   tolerance test, 18–19, 32, 128  
 glulisine, 18*t*, 71, 72*t*  
 glyburide, 68, 77  
 glycated hemoglobin, 8*t*, 31–33  
 glycated serum protein assays, 33  
 glycemia patterns, 28*f*  
 glycemic control, 14–15, 69–77, 91, 103, 138. *See also* glucose assessment, 26–34, 32*t*–33*t*  
 glycemic index (GI), 29, 53, 55  
 glycogen, 116  
 glycosylated hemoglobin. *See* A1C (glycosylated hemoglobin)  
 growth. *See* fetal  
*Guidelines for Perinatal Care* (American Academy of Pediatrics and the American College of Obstetricians and Gynecologists [AAP/ACOG] 2017), 118

## H

Harris Benedict equation, 45  
 heart disease. *See* cardiovascular disease (CVD); ischemic heart disease  
 heart failure, 6*t*  
 hemodialysis, 32*t*  
 hemoglobin, 31–32, 58  
 hemoglobin A<sub>1c</sub>. *See* A1C (glycosylated hemoglobin)  
 hemoglobinopathies, 32*t*

- hemorrhage, 12, 112, 112*t*  
 hepatic gluconeogenesis, 71, 76  
 hepatitis B virus, 11*t*  
 herbal medicines and supplements, 60  
 high-amylose foods, 55–56  
 hirsutism, 146  
 HIV testing, 11*t*  
 hormonal contraception, 139, 140*t*,  
 141, 142*t*–143*t*  
 hormonal contraception, non-LARC,  
 140*t*, 144–147  
 human chorionic gonadotropin  
 (hCG), 85, 97  
 human insulin, 18*t*, 70  
 human placental lactogen, 31, 70  
 hydrocephalus, 110  
 $\beta$ -hydroxybutyrate levels, 45  
 $\beta$ -hydroxybutyric acid, 34, 45  
 hyperbilirubinemia, 6*t*, **115–116**  
 hyperemesis, **97–100**, 99*t*  
 hyperemesis gravidarum, 97  
 hyperglycemia, 26, 31  
   calories, 44–45  
   at conception, 6  
   congenital anomalies, 102, 111  
   continuous subcutaneous insulin  
   infusion (CSII), 15–17  
   corticosteroid, 75, 101  
   diabetic ketoacidosis (DKA), 100  
   effects on fetus, 69  
   fasting, 16, 111  
   fetal, 101, 103  
   insulin pumps, 73  
   intermediate-acting insulin, 16  
   intrauterine growth restriction  
   (IGR), 113  
   ketonuria, 34  
   labor and delivery, 75  
   maternal, 75, 88, 93, 96, 101, 103  
   medication management, 69  
   metabolic abnormalities, 7  
   postprandial, 49  
   spontaneous abortion (SAB), 6  
 Hyperglycemia and Adverse  
 Pregnancy Outcomes (HAPO)  
 study, 28, 32  
 hyperinsulinemia, 87, 101, 103, 111  
 hyperinsulinism, 111  
 hypertension, 2, 101–102. *See also*  
 preeclampsia  
   antenatal testing, 88, 91  
   contraception, 139, 141, 142*t*,  
   145–146  
   control recommendations, 12  
   exercise, 61  
   gestational, 76  
   intrauterine growth restriction  
   (IGR), 113  
   metabolic syndrome, 119  
   pregnancy-induced, 5*t*  
   prepregnancy assessment,  
   11–13  
   ultrasound, 88  
 hyperthyroidism, 98  
 hypertriglyceridemia, 57  
 hyperviscosity, 6*t*  
 hypocalcemia, 6*t*, 114–116  
 hypoglycemia, 6*t*, **74–75**, 116*t*  
   brain injury, 117  
   cardiomyopathy, 111  
   congenital anomalies, 111  
   continuous glucose monitoring  
   (CGM), 30  
   dietary management, 49  
   hypocalcemia, 114–115  
   insulin dosage adjustment, 100  
   insulin pumps, 73  
   insulin-induced, 29  
   lactation, 129–130  
   maternal, 5*t*  
   middle-of-the-night, 31  
   neonatal, 68, 75–77, 93, 108, 114,  
   117*t*, 127  
   neonatal resuscitation, 108  
   nocturnal, 16–17, 53, 71  
   nursery care, 116  
   oral diabetic agents, 76–77  
   postpartum, 126  
   rebound, 117  
   self-monitoring of blood glucose  
   (SMBG), 29  
   unawareness, 11, 30  
 hypomagnesemia, 6*t*, 114–116  
 hypotension, 33*t*, 113  
 hysteroscopic surgical tubal  
 occlusion, 138

- I**
- implants, 138, 140*t*, 142*t*, 145–147
  - indomethacin, 75, 101
  - induction, 75, 75*t*, 91
  - infection, 5*t*, 13, 31, 60, 102, 109, 129
  - infertility, 2, 11, 13
  - Institute of Medicine (IOM), 43
  - insulin, 31. *See also* oral
    - adjustments, 100
    - analogs, 16, 29–30, 70–71
    - antenatal, 70–74, **70–74**, 72*t*, 73*f*
    - approved for pregnancy, 18*t*
    - aspart, 16, 18*t*, 71, 72*t*
    - aspart glulisine, 18*t*, 71, 72*t*
    - basal, 16, 69, 71
    - breast-feeding, 127–128, 130
    - calculations, 72*t*
    - continuous subcutaneous insulin infusion (CSII), 15–17, 68, **73–75**, 102
    - degludec, 18*t*
    - detemir (Levemir), 16, 18*t*, 71
    - discovery, 5
    - dosage adjustment, 74
    - dosing regimen, 73*f*
    - drip, 75
    - endogenous, 69
    - exercise, 49, 61, 70, 74
    - glargine (Lantus), 16, 18*t*, 71
    - glulisine, 18*t*
    - human, 70
    - inhaled human, 18*t*
    - intermediate-acting, 16, 71, 75*t*–76*t*
    - intravenous (IV), 75
    - during labor and delivery, 75, 75*t*–76*t*
    - lispro, 16, 18*t*
    - long-acting, 16, 68, 100
    - morning sickness, 98, 100–103
    - NPH (neutral protamine Hagedorn), 16, 18*t*, 71
    - onset, peak, and duration, 72*t*
    - pancreatic secretion, 77
    - plasma, 70
    - postpartum, 70, 127–128, 130
    - premixed, 68
    - preterm delivery, 74–75
    - pumps, 15, 68, **73–75**, 102
    - rapid-acting, 29–30
    - regimen, 15, 71, 127
    - regular, 16, 18*t*, 29
    - requirements, 68–69, 70*f*, 102
    - resistance, 14, 51–52, 56, 69–70, 141, 146
    - sensitivity, 27, 45, 73, 77
    - short-acting, 30, 68, 100
    - therapy, 15–17, 15*t*
  - intermittent CGM (iCGM), 30
  - intrauterine devices (IUDs), 140*t*, **141**
    - copper IUD (Cu-IUD), 138, 142*t*, 144–145
    - levonorgestrel (LNG) - releasing, 138, 144, 144*t*
    - progestin-releasing, 138
  - intrauterine growth restriction (IGR), 6*t*, 59, 111, **113**
  - intravenous (IV)
    - fluids, 100, 102
    - insulin, 75
  - iron, 47*t*, **58**, 99, 99*t*, 131*t*, 133, 144
  - iron deficiency anemia, 58–89
  - ischemic heart disease, 2, 10, 13, 13*t*
- K**
- kangaroo care, 127
  - karyotyping, 86
  - ketoacidosis. *See* diabetic ketoacidosis (DKA)
  - ketone strips, 34
  - ketonemia, 33–34, 33*t*
  - ketones, 45, 48
  - ketonuria, **33–34**, 33*t*, 45, 97
  - ketosis starvation, 52
  - kidney disease, 12
- L**
- labetalol, 12
  - labor, 75*t*–76*t*, 89
    - dystocia, 93
    - induction, 75, 75*t*, 91
    - premature, 86
    - preterm, 5*t*, 11, 69, 74–75, 92, 96, 100–101, 110, 113–114
  - laceration, 5*t*

lactation, 49*t*, 51, 129–130, 130*t*.

See also breast-feeding

lactogenesis, 129

laser photocoagulation, 12

late deceleration, 89–90

lifestyle management

dietary guidelines, 50*t*

exercise, 61

food safety, 59–60, 59*t*

healthy, 14

individualized meal planning and recordkeeping, 48–49, 49*t*–50*t*

macronutrients, 49, 50–57, 51*t*, 54*t*–55*t*, 133

micronutrients, 57–59

nutritional management in

pregnancy, 45–48, 46*t*–47*t*

weight gain recommendations, 43–45, 43*t*

$\alpha$ -Linolenic acid, 46*t*, 131*t*

lipid levels, 138–139, 141, 146. See also dyslipidemia

lispro, 16, 18*t*, 71

liver function tests, 97

long-acting reversible contraception (LARC), 9

implants, 145

intrauterine devices (IUDs), 138, 140*t*, **141**, 142*t*, **144–145**, 144*t*

long-term follow-up, 119–120

## M

macronutrients, 49, 50–57, 51*t*, 54*t*–55*t*, 133

macrosomia, 6*t*, 108, 110, **112–113**, 112*t*

calorie restriction, 45–46

continuous glucose monitoring (CGM), 30

dietary fiber, 53

fetal surveillance, 84*t*

glucose control, 111

mode of delivery, 91

rates of, 44–45, 68, 77

risk of, 30, 55, 69, 90–91

macular edema, 12

magnesium sulfate, 75, 102

malabsorption, 58

malpresentation, 93

management, prepregnancy, 2–3, **14–17**, 15*t*

*Management of Pre-existing Diabetes and Pregnancy*, 55

mastitis, 129

maternal

age, 2, 51, 83

complications in diabetic pregnancy, 5*t*

glucose, 27, 29, 31, 52, 75, 93, 110, 114

glucose homeostasis, 114

glycemia, 103, 110, 114

hyperglycemia, 75, 88, 93, 96, 101, 103 (See also hyperglycemia)

monitoring, 93

mortality, 5

plasma volume, 56

red cell mass, 58

tissue, 56

vascular disease, 88

meal plan, 14, 31, 48–50, 52–56, 60, 98, 128–129

meclizine, 99

medical nutrition therapy (MNT), 11, 17, 41, 46, 130

medication management. See also insulin

antenatal insulin use, 70–74, 72*t*–73*t*, 73*f*

antiemetic, 100

dosage adjustment, 74

hyperglycemia, 69

hypoglycemia, 74

insulin pumps, **73–75**

during labor and delivery, 75, 75*t*–76*t*

metabolic changes during pregnancy, **68–77**, 70*f*, 72*t*–73*t*, 75*t*–76*t*

nausea, 99–100

oral antidiabetic agents, 76–77

pregnancy, 126

preterm delivery, 74–75

menopause, 9

menstrual period, 10

mercury, 60



metabolic  
 abnormalities, 7, 116  
 changes in pregnancy, 68–70, 70*f*  
 control measures, 31–33, 32*t*  
 syndrome, 119  
 metabolism, 46  
 metformin, 15, 19, 68, 76–77, 128  
 methyl dopa, 12  
 metoclopramide, 99–100  
 micronutrients, 57–59, 133  
 mineral supplementation, 59  
 miscarriage, 59–60, 84*t*, 103  
 molar pregnancy, 97  
 monounsaturated fat (MUFA), 57  
 morning sickness. *See* hyperemesis  
 MRI (magnetic resonance imaging), 117  
 multidisciplinary team, 46  
 multiple daily injections (MDI),  
 15–17, 73  
 multiple-marker screening, 85  
 multiples of the median (MOM), 85  
 multivitamin, 98. *See also* vitamins

## N

nausea. *See* hyperemesis  
 neonatal, 5  
 bone metabolism, 58  
 hypoglycemia, 68, 75–77, 93,  
 108, 114, 117*t*, 127  
 infants with diabetic mothers,  
 108–120, 110*t*, 112*t*–113*t*,  
 116*t*–118*t*  
 intensive, 2  
 morbidity, 103, 108–109  
 mortality, 110  
 newborn outcomes, 110–115,  
 110*t*, 112*t*, 113*t*  
 renal failure, 12  
 resuscitation, 108  
 neonatologist, 9  
 nephrologist, 9  
 nephropathy, 5, 13, 56, 91, 101–102,  
 138, 142*t*  
 neurological instability, 6*t*  
 neuropathy, 2, 5*t*, 11*t*, 138  
 newborn outcomes, 110–115, 110*t*,  
 112*t*–113*t*  
 nifedipine, 12

nonstress test (NST), 84*t*, 88–90,  
 89*f*–90*f*, 103  
 normoglycemia, 26–28, 28*f*  
 NPH (neutral protamine Hagedorn),  
 16, 18*t*, 71  
 nuchal translucency, 84*t*, 85, 88  
 nurse educators, 9  
 nursery care, 115–118, 116*t*–118*t*  
 nutrition, 2  
 assessment, 45  
 deficiencies, 133  
 macronutrients, 133  
 management  
 gestational diabetes mellitus  
 (GDM), 48  
 preexisting diabetes, 45–46,  
 46*t*–47*t*  
 pregnancy, 45–48, 46*t*–47*t*  
 medical nutrition therapy  
 (MNT), 11, 17, 41, 46, 130  
 micronutrients, 133  
 obesity, 44–45  
 postpartum, 130, 130*t*–132*t*,  
 132–133  
 nutritionist, 46

## O

obesity, 14, 43  
 calorie restriction, 44–45  
 congenital malformations with, 6  
 contraception, 142*t*  
 development of, 69  
 lactation, 51  
 nutrition, 44–45  
 postpartum, 45  
 obstetric care, 3  
 offspring adiposity, 119  
 offspring cognitive abilities, 119–120  
 oligohydramnios, 89  
 oligosaccharides, 55–56  
 omega-3 (n-3) fatty acids, 57  
 ondansetron, 100  
 ophthalmologist, 9. *See also* eye exams  
 oral  
 antidiabetic agents  
 glyburide, 68, 77  
 metformin, 15, 19, 68,  
 76–77, 128

- contraceptives, 138–139, 140*t*, 141  
 glucose tolerance test, 18–19, 32, 128  
 progestin-only oral  
 contraception (PO-OC), 138, 140*t*, **146–147**
- organogenesis, 7, 10, 69  
 organomegaly, 6*t*  
 oxidative stress, 7
- P**
- pancreatic  $\beta$ -cell insulin secretion, 27  
 parathyroid hormone, 98, 114–115  
 pediatrician, 9  
 pelvic inflammatory disease (PID), 144  
 perinatal deaths, 102–103  
 perinatal morbidity, 6*t*  
 perinatal mortality, 5, 6*t*, 58  
 permanent sterilization. *See* sterilization  
 physical activity, 14, 28, 51*t*, 52, 71, 132. *See also* exercise  
 placenta, 16, 68, 70, 76  
 plasma, 56  
 glucose, 19, 27, 48, 71, 88  
 insulin, 70  
 triglyceride fatty acids, 45  
 polycystic ovarian syndrome, 77  
 polyhydramnios, 5*t*, 88  
 polyunsaturated fatty acids (PUFA), 57  
 postpartum  
 care, 127–129  
 concerns, 126–133, 130*t*–132*t*  
 contraception, 138, 143*t*, 147, 148*t*  
 depression, 128–129  
 insulin, 70, 127–128, 130  
 nutrition, 130, 130*t*–132*t*, 132–133  
 thyroiditis, 128–129  
 weight retention, 43  
 postprandial  
 blood glucose, 15*t*, 16, 27, 29–30, 52  
 hyperglycemia, 49  
 potassium, 33*t*, 100  
 preconception care. *See* prepregnancy  
 preconception counseling, 44  
 prediabetes, 3  
 preeclampsia, 5*t*, 11*t*, 12–13, 96, **101–102**, 110, 128  
 preexisting diabetes. *See* diabetes  
 pregnancy  
 complications in, 5*t*  
 diabetes complications, 96–103, 99*t*  
 diabetogenic stress, 69  
 glycemic targets, 30  
 meal plan for, 49*t*  
 medication management, **68–77**, 70*f*, 72*t*–73*t*, 75*t*–76*t* (*See also* medication management)  
 metabolic changes during, 68–70, 70*f*  
 molar, 97  
 normoglycemia during, 27–28, 28*f*  
 nutritional management in, 45–48, 46*t*–47*t*  
 planned, 2  
 potential contraindications, 13*t*  
 rate by birth control method, 140*t*  
 risks, 5*t*–6*t*  
 unplanned, 138–139  
 pregravid BMI, 44  
 prematurity, 86, 115  
 prenatal care, 18  
 prenatal vitamin, 2, 11*t*, 133. *See also* vitamins  
 prepregnancy  
 assessment, 2–3, **11–14**, 11*t*, 13*t*  
 counseling, 2–3, **9–11**, 9*t*  
 management, 2–3, **14–17**, 15*t*  
 medication management, 126  
 weight, 126, 132  
 preterm. *See also* labor  
 birth, 5*t*, 11, 69, 74–75, 92, 96, **100–101**, 110, 113–114  
 delivery, 74–75  
 prochlorperazine, 99  
 progesterone, 31, 70, 141, 147  
 progestin, 140*t*, 141, 144–146  
 progestin-only oral contraception (PO-OC), 138, 140*t*, **146–147**  
 prolactin, 129  
 promethazine, 99  
 propranolol, 112  
 protein, 29, 46–48, 50, **56**, 59, 98, 130–133

proteinuria, 13*t*, 101–102  
 psychosocial consultation, 3  
 puberty, 9  
 pyelonephritis, 5*t*  
 pyridoxine (vitamin B<sub>6</sub>), 99

## R

randomized controlled trials (RCTs),  
 16, 27–28, 55, 71, 77, 127  
 real-time CGM (rtCGM), 30  
 rebound hypoglycemia, 117  
 recommended daily allowance (RDA),  
 52, 133  
 recordkeeping, 48–49, 49*t*  
 red blood cell, 32*t*  
 red cell mass, 58  
 registered dietician. *See* dietician  
 regular insulin, 16, 18*t*, 29  
 renal  
   disease, 12–13, 102, 146  
   function, 102  
   insufficiency, 10, 12, 13*t*  
 resistant starch, 55–56  
 respiratory distress, 108, 113–114, 113*t*  
 respiratory distress syndrome (RDS),  
 6*t*, 69, 87  
 resuscitation, 118, 118*t*  
 retinal  
   disease, 128  
   hemorrhage, 12  
   status, 12  
   surveillance, 138–139  
   vasculature, 145  
 retinopathy, 2, 5*t*, 10, 12, 138  
 risk assessment, 82  
 ritodrine, 74  
 rubella, 11*t*

## S

salpingectomy, 138  
 saturated fat (SFA), 15, 56  
 seizure, 74, 102, 115  
 self-monitoring of blood glucose  
 (SMBG), 26–28  
   breast-feeding, 130  
   carbohydrates, 53  
   gestational diabetes mellitus  
   (GDM), 29–30

glucose levels, 26–30, 32, 46, 49,  
 53, 128, 130  
 hypoglycemia, 29  
 meal plans, 49  
 nutrition, 53  
 postpartum, 128  
 site of, 29  
 timing of, 29–30  
 serum  
   cord-blood serum C-peptide  
   levels, 28  
   creatinine level, 11*t*, 12–13, 13*t*,  
   102  
   glycated serum protein assays, 33  
   lipid levels, 138–139, 141, 146  
   maternal serum  $\alpha$ FP (MS $\alpha$ FP),  
   83, 85  
   potassium, 33*t*  
   prolactin, 129  
 shoulder dystocia, 93  
 sickle cell disease, 32*t*, 84*t*  
 skin-to-skin care, 127  
 small-for-gestational-age (SGA), 44–45  
 smoking, 2, 11*t*  
 sodium, 15, 47*t*, 57, 132*t*  
 spermicides, 139  
 spina bifida, 84*t*, 110  
 spontaneous abortion (SAB), 2, 6–8,  
 57, 59, 77, 139  
 Stanford-Binet scores, 45  
 starvation ketosis, 52  
 sterilization, 9, 13, 138–139, 140*t*, 147,  
 148*t*  
 stillbirth, 6*t*, 60, 92, 103  
 stress, 31  
 subcutaneous interstitial tissue  
   glucose, 30  
 sulfonylurea, 77  
 supplemental aid programs, 11  
 surfactant production, 101  
 surgical ligation, 138  
 sweeteners, 60  
 sympathomimetics, 74  
 syphilis, 11*t*

## T

Tay-Sachs disease, 83, 84*t*  
 teratogenicity, 2, 7, 14, 102, 111

terbutaline, 74  
 tetany, 116*t*  
 thalassemia, 84*t*  
 thyroid  
     disease, 11, 98  
     function tests, 97  
     hormone, 98, 114–115  
     studies, 11*t*  
 thyroid stimulating hormone (TSH),  
     11*t*, 98  
 thyroiditis, 128–129  
 tissue glucose, 30  
 tocolysis, 75, 101  
 trans fat, 15, 56  
 transdermal patches, 138  
 transfusion, 32*t*  
 triglycerides, 27, 44–45, 57, 141  
 trisomy 21, 83, 84*t*  
 type 1 diabetes (T1D), 2, 5, 10, 11*t*, 12,  
     16, 31  
     breast-feeding, 129–130  
     continuous glucose monitoring  
         (CGM), 30  
     detemir, 71  
     dietary management, 49  
     first trimester, 69  
     macrosomia in, 45–46  
     morbidity and mortality, 6  
     NPH (neutral protamine  
         Hagedorn), 71  
     postpartum, 127–128  
     stillbirth, 103  
 type 2 diabetes (T2D), 2–5, 10, 11*t*, 12,  
     16–19  
     breast-feeding, 129–130  
     continuous glucose monitoring  
         (CGM), 30  
     development of, 69  
     meal plans, 49  
     morbidity and mortality, 6  
     postpartum, 127–128  
     stillbirth, 103  
     undiagnosed, 6

## U

ultrasound, 82, 84*t*, **87–88**  
 umbilical blood flow, 85*t*

U.S. Food and Drug Administration  
 (FDA), 16, 71  
 U.S. Medical Eligibility Criteria (U.S.  
 MEC 2010), 141, 142*t*  
 uterine contractions, 90*f*

## V

vaginal bleeding, 109  
 vaginal delivery, 82, 91, 93, 112  
 vaginal ring, 138, 140*t*, 145  
 Valsalva maneuver, 12  
 vascular  
     complications, 9  
     disease, 57, 88, 90, 111, 113, 130,  
         132 (*See also* cardiovascular  
         disease (CVD))  
     maternal disease, 88  
     sequelae, 141  
 vitamins, 131*t*  
     B<sub>6</sub>, 99  
     B<sub>12</sub>, 58, 133  
     C, 33  
     D, **58**  
     *Dietary Reference Intakes for  
         Vitamin D and Calcium (IOM  
         2010)*, 58  
     fat-soluble, 56  
     multi, 98  
     prenatal, 2, 11*t*, 133  
     supplementation, 59  
 vomiting. *See* hyperemesis

## W

weight. *See also* obesity  
 birth, 13, 27–30, 45, 55–61,  
     108–110, 117, 129  
 gain, 41–45, 43*t*, 51  
 loss, 3, 14, 19, 44  
 postpartum, 43  
 prepregnancy, 126, 132  
 World Health Organization (WHO),  
     129, 144

## Z

zinc, 47*t*, 58, 131*t*